

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

1. FURTHER INFORMATION ABOUT OUR COMPANY

A. Incorporation

On April 26, 2011, the predecessor of our Company, Shenzhen Yusheng Medical Technology Co., Ltd. (深圳玉升醫療科技有限公司), was established as a limited liability company in Shenzhen, the PRC, with a registered capital of RMB2,600,000. In July 2013, our Company was renamed as Medcaptain Medical Technology Co., Ltd. (深圳麥科田生物醫療技術有限公司). On November 19, 2020, our Company was converted into a joint stock company with limited liability and Medcaptain Medical Technology Co., Ltd. (麥科田生物醫療技術股份有限公司).

We have established a place of business in Hong Kong at Room 1916, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong, and have been registered as a non-Hong Kong company in Hong Kong under Part 16 of the Companies Ordinance on August 14, 2025. Ms. LEE Mei Yi (李美儀) and Ms. SIOU Yuet Chew Grace have been appointed as our agent for the acceptance of services of process and notices on behalf of our Company in Hong Kong.

As we are incorporated in the PRC, we are subject to the relevant laws and regulations of the PRC. A summary of the relevant aspects of laws and regulations of the PRC and our Articles of Association is set out in “Regulatory Overview” of this document and Appendix III to this document.

B. Changes in the Share Capital of our Company

Immediately following the unwinding of the WVR structure, the Conversion of the Unlisted Shares into H Shares and upon completion of the [REDACTED], without taking into account any H Shares which may be issued pursuant to the [REDACTED], our registered share capital will be increased to [REDACTED], comprising [REDACTED] H Shares and [REDACTED] Unlisted Shares, of which [REDACTED] H Shares are to be issued and sold under the [REDACTED], representing [REDACTED]%, and [REDACTED] of our enlarged registered share capital, respectively. Save as disclosed, there has been no alteration in the share capital of our Company during the two years immediately preceding the date of this document.

C. Resolutions of the Shareholders of our Company

On December 16, 2024, the shareholders of our Company passed, among other things, the following resolutions:

- (i) the issue by our Company of H Shares of nominal value of RMB1.00 each and such Shares be [REDACTED] on the Stock Exchange;
- (ii) the amount of the H Shares to be [REDACTED] shall be no more than [REDACTED]% of the total share capital as enlarged immediately following the [REDACTED] (before the exercise of the [REDACTED]);
- (iii) the grant of the [REDACTED] in respect of no more than [REDACTED] of the number of H Shares issued pursuant to the [REDACTED];
- (iv) with effect from the [REDACTED], (a) the WVR structure be unwound, (b) each issued Class A Share and Class B Share be re-designated to one H Share or Unlisted Share, as the case may be, and (c) after the re-designation, each holder of the issued Shares of be entitled to one vote per Share at a general meeting of our Company;

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

- (v) subject to the completion of the [REDACTED], the Articles of Association have been approved and adopted, which shall only become effective from the [REDACTED], and our Board has been authorized to amend the Articles of Association in accordance with any comments from the Stock Exchange and the relevant PRC regulatory authorities; and
- (vi) approving our Board to handle all matters relating to, among other things, the issue of H Shares and the [REDACTED] of H Shares on the Stock Exchange.

D. Subsidiaries of Our Company

(i) Subsidiaries

Certain details of our subsidiaries are set forth in the Accountants’ Report in Appendix I to this document.

(ii) Changes in the share capital of subsidiaries

The following changes in the share capital of our subsidiaries took place during the two years immediately preceding the date of this document.

- (i) On August 1, 2024, Mabsky Technology was incorporated in the PRC with an authorised share capital of RMB20,000,000;
- (ii) On June 17, 2025, Medcaptain Sichuan was incorporated in the PRC with an authorised share capital of RMB50,000,000;
- (iii) On July 15, 2025, Medcaptain Jiangsu was incorporated in the PRC with an authorised capital of RMB30,000,000;
- (iv) On September 15, 2025, the registered capital of Medcaptain Software increased from RMB1,000,000 to RMB4,500,000;
- (v) On December 30, 2025, the registered capital of Caring Medical increased from RMB22,500,000 to RMB52,500,000; and
- (vi) On December 31, 2025, the issued share capital of Medcaptain HK increased from HK\$280,300,000 to HK\$308,410,000.

Save as disclosed above, there has been no alteration in the share capital of any of our subsidiaries within the two years immediately preceding the date of this document.

2. FURTHER INFORMATION ABOUT OUR BUSINESS

A. Summary of Our Material Contracts

We have entered into the following material contracts (not being contracts entered into in the ordinary course of business) within two years preceding the date of this document and a copy of each has been delivered to the Registrar of Companies in Hong Kong for registration:

- (i) the [REDACTED]
- (ii) [●]; and
- (iii) [●].

APPENDIX IV STATUTORY AND GENERAL INFORMATION

B. Our Material Intellectual Property Rights

(i) Patents

As of the Latest Practicable Date, we were the registered owner of and had the right to use the following patents which we consider to be or may be material to our business:

No.	Publication/ Application Number	Description	Patent Type	Place of Registration	Registered Owner	Date of Application	Expiry Date
1. . .	CN201810373392.4	Infusion pumps and automatic stopping methods for infusion pumps (輸液泵及輸液泵的自動止液方法)	Invention	PRC	Our Company	April 24, 2018	April 23, 2038
2. . .	CN201911023023.3	Touch Panel Calibration Methods and Related Products (觸摸屏校準方法及相關產品)	Invention	PRC	Our Company	October 25, 2019	October 24, 2039
3. . .	CN201811265931.9	A PCA infusion device and a method, device and storage medium for early unlocking (一種PCA輸注裝置及提前解除鎖定的方法、裝置及存儲介質)	Invention	PRC	Our Company	October 29, 2018	October 28, 2038
4. . .	CN201910715064.2	Methods of sample analysis (樣品分析的方法)	Invention	PRC	Our Company	July 31, 2019	July 30, 2039
5. . .	CN201910803917.8	A platelet inhibition rate assay kit and a method for its preparation and assay thereof (一種血小板抑制率檢測試劑盒及其製備方法和檢測方法)	Invention	PRC	Our Company	August 28, 2019	August 27, 2039
6. . .	CN201210370924.1	An automatic syringe pump (一種自動注射泵)	Invention	PRC	Our Company	September 29, 2012	September 28, 2032
7. . .	CN201310029699.X	A kind of electric stop liquid clip control method and infusion pump (一種電動止液夾控制方法及輸液泵)	Invention	PRC	Our Company	January 25, 2013	January 24, 2033
8. . .	CN201310038886.4	An infusion pump (一種輸液泵)	Invention	PRC	Our Company	February 1, 2013	January 31, 2033
9. . .	CN201310041162.5	An infusion pump (一種輸液泵)	Invention	PRC	Our Company	February 1, 2013	January 31, 2033
10. .	CN201310042029.1	An infusion pump with motorized control of the stop clip (一種電動控制止液夾的輸液泵)	Invention	PRC	Our Company	February 4, 2013	February 3, 2033
11. .	CN201310042125.6	An infusion pump with motorized control of the stop clip (一種電動控制止液夾的輸液泵)	Invention	PRC	Our Company	February 4, 2013	February 3, 2033

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Publication/ Application Number	Description	Patent Type	Place of Registration	Registered Owner	Date of Application	Expiry Date
12.	CN201310042655.0	A syringe pump transmission device (一種注射泵傳動裝置)	Invention	PRC	Our Company	February 4, 2013	February 3, 2033
13.	CN201310042030.4	A syringe pump (一種注射泵)	Invention	PRC	Our Company	February 4, 2013	February 3, 2033
14.	CN201310071236.X	Infusion pumps with electrically controlled pump doors and stop clips (電動控制泵門和止液夾的輸液泵)	Invention	PRC	Our Company	March 6, 2013	March 5, 2033
15.	CN201310634721.3	An infusion pump and its peristaltic device (一種輸液泵及其蠕動裝置)	Invention	PRC	Our Company	November 30, 2013	November 29, 2033
16.	CN201610066649.2	A syringe pump and its transmission device (一種注射泵及其傳動裝置)	Invention	PRC	Our Company	January 29, 2016	January 28, 2036
17.	CN201710076506.4	An infusion management method and system (一種輸液管理方法及系統)	Invention	PRC	Our Company	February 13, 2017	February 12, 2037
18.	CN201710262581.X	An infusion system (一種輸液系統)	Invention	PRC	Our Company	April 20, 2017	April 19, 2037
19.	CN201710262582.4	An infusion system (一種輸液系統)	Invention	PRC	Our Company	April 20, 2017	April 19, 2037
20.	CN201710340936.2	A loading and unloading cup device and a thromboelastography device (一種裝卸杯裝置及血栓彈力圖儀)	Invention	PRC	Our Company	May 15, 2017	May 14, 2037
21.	CN201710338292.3	A kind of lyophilization reaction container (一種凍乾反應容器)	Invention	PRC	Our Company	May 15, 2017	May 14, 2037
22.	CN201710339780.6	Detection device with micro-damping structure (具有微阻尼結構的檢測裝置)	Invention	PRC	Our Company	May 15, 2017	May 14, 2037
23.	CN201710337992.0	Microtorque measurement device and method (微扭矩測量裝置及方法)	Invention	PRC	Our Company	May 15, 2017	May 14, 2037
24.	CN201710337991.6	A Cup Removal Device and Thromboelastography Device (一種卸杯裝置及血栓彈力圖儀)	Invention	PRC	Our Company	May 15, 2017	May 14, 2037
25.	CN201710477530.9	Syringe pump drives and syringe pumps for their applications (注射泵傳動裝置及其應用的注射泵)	Invention	PRC	Our Company	June 21, 2017	June 20, 2037
26.	CN201810139168.9	syringe pump (注射泵)	Invention	PRC	Our Company	February 9, 2018	February 8, 2038

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Publication/ Application Number	Description	Patent Type	Place of Registration	Registered Owner	Date of Application	Expiry Date
27.	CN201910387177.4	Quality control test application method, apparatus, device, and computer-readable storage medium (質控測試申請方法、裝置、設備及計算機可讀存儲介質)	Invention	PRC	Our Company	May 9, 2019	May 8, 2039
28.	CN201910711892.9	Photomultiplier tube shielding structure and signal detection device (光電倍增管屏蔽結構及信號檢測裝置)	Invention	PRC	Our Company	July 31, 2019	July 30, 2039
29.	CN202010097730.3	Probes, primers, kits and assays for the detection of novel coronaviruses based on double loop-mediated thermostatic amplification technology (基於雙重環介導恆溫擴增技術檢測新型冠狀病毒的探針、引物、試劑盒及檢測方法)	Invention	PRC	Our Company	February 17, 2020	February 16, 2040
30.	CN202111676284.2	Infusion pump control method and related devices (輸注泵控制方法及相關裝置)	Invention	PRC	Our Company	December 31, 2021	December 30, 2041
31.	CN202210581579.X	Packaging device (包裝裝置)	Invention	PRC	Our Company	May 26, 2022	May 25, 2042
32.	CN201210008688.9	A clutch device and syringe pump (一種離合裝置及注射泵)	Invention	PRC	Medcaptain Life Science	January 12, 2012	January 11, 2032
33.	CN201310003547.2	A multi-module snap-in combination system (一種多模塊卡接組合系統)	Invention	PRC	Medcaptain Life Science	January 6, 2013	January 5, 2033
34.	CN201310040830.2	Infusion pumps with electrically controlled on/off pump doors (電動控制開關泵門的輸液泵)	Invention	PRC	Medcaptain Life Science	February 1, 2013	January 31, 2033
35.	CN201310071204.X	Infusion pumps with electrically controlled pump doors and stop clips (電動控制泵門和止液夾的輸液泵)	Invention	PRC	Medcaptain Life Science	March 6, 2013	March 5, 2033
36.	CN201310106718.4	A multi-module combined power supply system (一種多模塊組合供電系統)	Invention	PRC	Medcaptain Life Science	March 29, 2013	March 28, 2033
37.	CN202210665630.5	Clamping device and anastomosis clamp for endoscopes (夾合裝置及用於內窺鏡的吻合夾)	Invention	PRC	Vedkang Medical	June 14, 2022	June 13, 2042

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Publication/ Application Number	Description	Patent Type	Place of Registration	Registered Owner	Date of Application	Expiry Date
38.	CN202010025739.3	A method of braiding a stent and a stent made using the method (一種支架編織方法及使用該方法製成的支架)	Invention	PRC	Vedkang Medical	January 10, 2020	January 9, 2040
39.	CN202210475153.6	An endoscopic surgical instrument (一種內窺鏡下手術器械)	Invention	PRC	Vedkang Medical	April 29, 2022	April 28, 2042
40.	CN202310225453.3	A hemostatic clip assembly and a hemostatic clip comprising it (一種止血夾組件及包含其的止血夾)	Invention	PRC	Vedkang Medical	March 10, 2023	March 9, 2043
41.	CN201811120614.8	Method of molded connection of over-guided bile duct sampling forceps and guide wire through connectors of sampling forceps (過導絲膽道取樣鉗及取樣鉗的導絲通接頭的成型連接方法)	Invention	PRC	Changzhou Jiuhong	September 26, 2018	September 25, 2038
42.	CN202310225454.8	A hemostatic clip push-pull assembly with a latch, a hemostatic clip, and a tissue clamping device (一種帶有鎖扣的止血夾推拉組件、止血夾及組織夾閉裝置)	Invention	PRC	Changzhou Jiuhong	March 10, 2023	March 9, 2043
43.	CN202210188021.5	A biopsy valve for endoscopy (一種內窺鏡用活檢閥)	Invention	PRC	Changzhou Jiuhong	February 28, 2022	February 27, 2042
44.	CN202211239673.3	Clamping components and hemostats for endoscopes (夾閉組件及內窺鏡用止血裝置)	Invention	PRC	Changzhou Jiuhong	October 11, 2022	October 10, 2042
45.	CN201811485683.9	Laccase for use as a PCR preservative and method of preparation and application thereof (用作PCR防腐劑的裂解酶及其製備方法和應用)	Invention	PRC	Mabsky	December 6, 2018	December 5, 2038
46.	CN201310135993.9	Small double-jointed RNA virus detection kit and its detection method (小雙節RNA病毒檢測試劑盒及其檢測方法)	Invention	PRC	Mabsky	April 18, 2013	April 17, 2033

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Publication/ Application Number	Description	Patent Type	Place of Registration	Registered Owner	Date of Application	Expiry Date
47.	CN201210457269.3	Fluorescent quantitative PCR test kit for detection of Salmonella typhimurium and Paratyphoid A and its application (傷寒、甲型副傷寒沙門菌熒光定量PCR檢測試劑盒及其應用)	Invention	PRC	Mabsky	November 14, 2012	November 13, 2032
48.	CN201210068100.9	Test kits and methods for the detection of Bacillus cereus, Enterobacter sakazakii and Staphylococcus aureus (蠟樣芽孢桿菌、阪崎腸桿菌及金黃色葡萄球菌檢測試劑盒及檢測方法)	Invention	PRC	Mabsky	March 15, 2012	March 14, 2032
49.	CN200910190112.7	Preservation of PCR reaction reagents and reaction kits (PCR反應試劑的保存方法以及反應試劑盒)	Invention	PRC	Mabsky	September 8, 2009	September 7, 2029
50.	CN201580033747.X	Vaporizer (汽化器)	Invention	PRC	Penlon	May 26, 2015	May 25, 2035
51.	US15/776708	Syringe pump	Invention	United States	Our Company	July 20, 2016	July 12, 2037
52.	US16/256269	Apparatus for cup loading and unloading and thromboelastography machine	Invention	United States	Our Company	January 24, 2019	April 4, 2039
53.	GB2014018046	Filling system for a fluid medium	Invention	United Kingdom	Penlon	October 13, 2014	October 13, 2034
54.	EP2015730698	Vaporizer	Invention	European Union	Penlon	May 26, 2015	May 26, 2035
55.	GB2014009274	Vaporizer	Invention	United Kingdom	Penlon	May 23, 2014	May 23, 2034
56.	US15/313620	Vaporizer	Invention	United States	Penlon	May 26, 2015	May 26, 2035

(ii) Trademarks

As of the Latest Practicable Date, the following trademarks have been registered in the name of the relevant member of our Group which are considered by us to be or may be material to our business:

No.	Trademark	Place of Registration	Registered Owner	Registration No.	Class	Expiry Date
1.	麥科田	PRC	Our Company	13093532	10	December 27, 2034
2.	MEDCAPTAIN	PRC	Our Company	16649270	10, 44	May 27, 2036

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of Registration	Registered Owner	Registration No.	Class	Expiry Date
3. . .	麦科田	PRC	Our Company	64919383	5	November 20, 2032
4. . .	麦科田	PRC	Our Company	64915381	9	November 20, 2032
5. . .	麦科田	PRC	Our Company	64930435	10	November 20, 2032
6. . .	麦科田	PRC	Our Company	64926006	35	November 13, 2032
7. . .	麦科田	PRC	Our Company	64911938	37	November 13, 2032
8. . .	麦科田	PRC	Our Company	64911947	42	November 13, 2032
9. . .	麦科田	PRC	Our Company	64921808	44	November 13, 2032
10. .	麦科田	PRC	Our Company	64930476	41	November 13, 2032
11. .	MEDCAPTAIN	PRC	Our Company	64933823	9	September 13, 2033
12. .	MEDCAPTAIN	PRC	Our Company	64925069	37	November 13, 2032
13. .	MEDCAPTAIN	PRC	Our Company	64919498	44	September 13, 2033
14. .	MEDCAPTAIN	PRC	Our Company	64978639	5	August 20, 2033
15. .	MEDCAPTAIN	PRC	Our Company	64972992	10	August 20, 2033
16. .	MEDCAPTAIN	PRC	Our Company	64955698	35	August 20, 2033
17. .	MEDCAPTAIN	PRC	Our Company	64925463	41	November 13, 2032
18. .		PRC	Runpu Biotech	8955260	5	January 13, 2032
19. .	MABSKY	PRC	Mabsky	19600385	5	May 27, 2027
20. .	生科原	PRC	Mabsky	19600548	5	May 27, 2027
21. .	MABSKY	PRC	Mabsky	19379097	9	June 20, 2027
22. .	生科原	PRC	Mabsky	19378891	9	April 27, 2027
23. .	MABSKY	PRC	Mabsky	19600976	10	May 27, 2027
24. .	生科原	PRC	Mabsky	19601043	10	May 27, 2027
25. .	MABSKY	PRC	Mabsky	19379471	35	June 20, 2027
26. .	生科原	PRC	Mabsky	19379381	35	April 27, 2027
27. .	MABSKY	PRC	Mabsky	19379204	42	April 27, 2027

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of Registration	Registered Owner	Registration No.	Class	Expiry Date
28.		PRC	Mabsky	19379098	42	April 27, 2027
29.		PRC	Mabsky	19601004	44	May 27, 2027
30.		PRC	Mabsky	19601291	44	May 27, 2027
31.		PRC	Vedkang Medical	17676680	10	October 6, 2026
32.		PRC	Vedkang Medical	17676632	10	January 20, 2027
33.		PRC	Vedkang Medical	23068179	35	March 6, 2028
34.		PRC	Vedkang Medical	46665254	10	April 6, 2031
35.		PRC	Vedkang Medical	69568889	9	July 27, 2033
36.		PRC	Vedkang Medical	69555511	37	July 27, 2033
37.		PRC	Vedkang Medical	69555356	42	August 13, 2033
38.		PRC	Vedkang Medical	69562388	44	July 27, 2033
39.		PRC	Vedkang Medical	69568885	9	July 27, 2033
40.		PRC	Vedkang Medical	69575036	37	July 27, 2033
41.		PRC	Vedkang Medical	69562732	42	July 27, 2033
42.		PRC	Vedkang Medical	69556989	44	July 27, 2033
43.		PRC	Changzhou Jiu Hong	10220291	10	January 20, 2033
44.		PRC	Changzhou Jiu Hong	23067979	35	May 13, 2028
45.		PRC	Changzhou Jiu Hong	23068348	35	October 13, 2028
46.		PRC	Changzhou Jiu Hong	46656961	10	January 20, 2031
47.		PRC	Changzhou Jiu Hong	46647780	10	January 27, 2031
48.		PRC	Changzhou Jiu Hong	61457823	10	June 13, 2032
49.		PRC	Changzhou Jiu Hong	61447419	10	June 13, 2032

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of Registration	Registered Owner	Registration No.	Class	Expiry Date
50.		PRC	Changzhou JiuHong	69561174	37	November 20, 2033
51.		PRC	Changzhou JiuHong	69566865	42	October 20, 2033
52.		PRC	Changzhou JiuHong	69569192	44	August 6, 2033
53.		PRC	Changzhou JiuHong	69575248	37	November 20, 2033
54.		PRC	Changzhou JiuHong	69559522	42	November 20, 2033
55.	MEDCAPTAIN	European Union	Our Company	18717335	5; 10; 35	June 16, 2032
56.	MEDCAPTAIN	Hong Kong	Our Company	305985802	5; 10; 35	June 16, 2032
57.	MEDCAPTAIN	Taiwan	Our Company	111043978	5; 10; 35	December 15, 2032
58.	MEDCAPTAIN	South Africa	Our Company	2022/18608	5; 35	June 17, 2032
59.	MEDCAPTAIN	Peru	Our Company	956537-2022	5; 10	October 25, 2032
60.	MEDCAPTAIN	Argentina	Our Company	4155615	5; 10	October 3, 2033
61.	MEDCAPTAIN	Ecuador	Our Company	1705868238	5; 10	February 3, 2033
62.	MEDCAPTAIN	Saudi Arabia	Our Company	362379 362381	5; 10	October 20, 2032
63.	MEDCAPTAIN	Chile	Our Company	1509310	5; 10; 35	May 4, 2033
64.	MEDCAPTAIN	Various (Note 1)	Our Company	1688154	5; 10; 35	July 5, 2032
65.		Hong Kong	Vedkang Medical	303468655	10	July 9, 2035
66.		European Union	Vedkang Medical	14341788	10	July 9, 2035
67.		European Union	Vedkang Medical	016203481	10	December 25, 2026
68.		South Korea, Australia, Turkey (Madrid registration)	Vedkang Medical	1310755	10	April 10, 2026
69.		Brazil	Vedkang Medical	909808724	10	October 31, 2027
70.		South Africa	Vedkang Medical	2015/19011	10	July 15, 2035
71.		Canada	Vedkang Medical	1737790/ TMA958739	10	December 22, 2031
72.		United Kingdom	Vedkang Medical	UK00914341788	10	July 9, 2035

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of Registration	Registered Owner	Registration No.	Class	Expiry Date
73.	Penlon	United Kingdom	Penlon	UK00913301254	10	September 26, 2034
74.	Penlon	United Kingdom	Penlon	UK00000785417	10	December 22, 2027

Note 1: Brazil, Switzerland, Algeria, Egypt, Indonesia, Israel, India, Japan, South Korea, Kazakhstan, Mexico, Malaysia, Norway, Philippines, Singapore, Serbia, United Kingdom, Ukraine, United States, Vietnam, United Arab Emirates, Canada, Australia, Bosnia and Herzegovina, Kenya, Morocco, North Macedonia and Tunisia

The class number represents the specifications of products or services which have already been applied for or registered. Detailed specifications of the products or services represented by that class number are set out in the relevant application forms or registration certificates.

(iii) Software Copyrights

As of the Latest Practicable Date, we had registered the following software copyrights which we consider to be material to our business:

No.	Name of Copyright	Place of Registration	Registered Owner	Registration No.	Date of Registration
1.	Medcaptain Medical SYS30 Series Syringe Pump Software (麥科田醫療SYS30系列注射泵軟件)	PRC	Our Company	2012SR038179	May 12, 2012
2.	Syringe Pump/Infusion Pump Accuracy Testing Software (注射泵/輸液泵精度測試軟件)	PRC	Our Company	2012SR040574	May 17, 2012
3.	MP-80 Series Multi-Channel Infusion Workstation Software V1.0 (MP-80系列多通道輸注工作站軟件V1.0)	PRC	Our Company	2018SR771101	September 21, 2018
4.	SYS30 Series Syringe Pump Software V1.0 (SYS30系列注射泵軟件V1.0)	PRC	Our Company	2018SR771107	September 21, 2018
5.	SYS-6010 Series Infusion Pump Software V1.0 (SYS-6010系列輸液泵軟件V1.0)	PRC	Our Company	2018SR771112	September 21, 2018
6.	MP-30 Series Syringe Pump Software V1.0 (MP-30系列注射泵軟件V1.0)	PRC	Our Company	2018SR774434	September 25, 2018
7.	MP-60 Series Infusion Pump Software V1.0 (MP-60系列輸液泵軟件V1.0)	PRC	Our Company	2018SR774470	September 25, 2018
8.	HP-30 Series Syringe Pump Software V2.0 (HP-30系列注射泵軟件V2.0)	PRC	Our Company	2019SR0405940	April 28, 2019

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Name of Copyright	Place of Registration	Registered Owner	Registration No.	Date of Registration
9.	HP TCI Syringe Pump Software V1.0 (HP TCI注射泵軟件V1.0)	PRC	Our Company	2019SR0405927	April 28, 2019
10.	HP-60 Infusion Pump Software V1.0 (HP-60輸液泵軟件V1.0)	PRC	Our Company	2019SR0405939	April 28, 2019
11.	HP-80 Multi-Channel Infusion Workstation Software V1.0 (HP-80多通道輸注工作站軟件V1.0)	PRC	Our Company	2019SR0405926	April 28, 2019
12.	SYS50 Series Syringe Pump Software V1.0 (SYS50系列注射泵軟件V1.0)	PRC	Our Company	2019SR0405938	April 28, 2019
13.	SYS-70 Infusion Pump Software V1.0 (SYS-70輸液幫浦軟件V1.0)	PRC	Our Company	2019SR0404213	April 28, 2019
14.	EP-60 Series Enteral Nutrition Pump Software V1.0 (EP-60系列腸內營養泵軟件V1.0)	PRC	Our Company	2019SR0404234	April 28, 2019
15.	VS31 Series Anesthesia Video Laryngoscope Software V1.0 (VS31系列麻醉視頻喉鏡軟件V1.0)	PRC	Our Company	2019SR0406023	April 28, 2019
16.	Automatic Chemiluminescence Immunoassay Analyzer Software V1.0 (全自動化學發光免疫分析儀軟件V1.0)	PRC	Our Company	2019SR0406021	April 28, 2019
17.	Haema T4 Thromboelastography Software V1.0 (Haema T4血栓彈力圖儀軟件V1.0)	PRC	Our Company	2019SR0406014	April 28, 2019
18.	MS-100 Infusion Information Acquisition System Software (Abbreviation: Infusion Monitoring Software) V1.2.0 (MS-100輸液信息採集系統軟件(簡稱:輸注監控軟件)V1.2.0)	PRC	Our Company	2021SR1335716	September 7, 2021
19.	Automatic Thromboelastography Software (全自動血栓彈力圖儀軟件)	PRC	Our Company	2021SR2175727	December 27, 2021
20.	Automatic Blood Analyzer Software (全自動血型分析儀軟件)	PRC	Our Company	2021SR2187996	December 28, 2021

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Name of Copyright	Place of Registration	Registered Owner	Registration No.	Date of Registration
21.	HP-80 MRI Magnetic Resonance Infusion Workstation Software (HP-80 MRI磁共振輸注工作站軟件)	PRC	Our Company	2022SR0249946	February 21, 2022
22.	iSpiro mobile application (iSpiro手機應用軟件)	PRC	Our Company	2023SR0257130	February 17, 2023
23.	Smart Analgesia Physician Mobile Application V1.0.0 (智能鎮痛醫生端手機應用軟件V1.0.0)	PRC	Our Company	2023SR0748380	June 29, 2023
24.	Smart Analgesia Patient Mobile Application V1.0.0 (智能鎮痛患者端手機應用軟件V1.0.0)	PRC	Our Company	2023SR0748379	June 29, 2023
25.	Brand Identity of Shenzhen Maketian Biomedical Technology Co. (深圳麥科田生物醫療技術股份有限公司品牌標識)	PRC	Our Company	國作登字-2023-F-0069590	April 19, 2023
26.	McCurtain Deep Vein Antithrombotic Pump Software V1.0.0.5 (麥科田深靜脈防血栓泵軟件V1.0.0.5)	PRC	Medcaptain Software	2016SR017836	January 25, 2016
27.	Macrotron MP-60SYS-6010 Infusion Pump Driver Software V1.15 (麥科田MP-60SYS-6010輸液泵驅動軟件V1.15)	PRC	Medcaptain Software	2017SR176839	May 12, 2017
28.	McCurtain MP-60SYS-6010 Infusion Pump UI Software V2.29 (麥科田MP-60SYS-6010輸液泵UI軟件V2.29)	PRC	Medcaptain Software	2017SR176847	May 12, 2017
29.	McCurtain MP-30 Syringe Pump UI Software V2.29 (麥科田MP-30注射泵UI軟件V2.29)	PRC	Medcaptain Software	2017SR176853	May 12, 2017
30.	Macrotron MP-30 Syringe Pump Driver Software V1.17 (麥科田MP-30注射泵驅動軟件V1.17)	PRC	Medcaptain Software	2017SR176845	May 12, 2017
31.	Makita MP-80 Multi-Channel Infusion Workstation Software V1.12 (麥科田MP-80多通道輸注工作站軟件V1.12)	PRC	Medcaptain Software	2017SR176849	May 12, 2017
32.	MP-900 Intelligent Infusion Management System V1.0 (MP-900智能輸注管理系統V1.0)	PRC	Medcaptain Software	2017SR176846	May 12, 2017

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Name of Copyright	Place of Registration	Registered Owner	Registration No.	Date of Registration
33.	McCurtain HP-30 Syringe Pump UI Software V1.3.0 (麥科田HP-30注射泵UI軟件V1.3.0)	PRC	Medcaptain Software	2017SR578504	October 20, 2017
34.	Makita HP-30 Syringe Pump Driver Software V1.3.0 (麥科田HP-30注射泵驅動軟件V1.3.0)	PRC	Medcaptain Software	2017SR577680	October 20, 2017
35.	McCurtain HP-60 Infusion Pump Safety Monitoring Software V1.3.0 (麥科田HP-60輸液泵安全監控軟件V1.3.0)	PRC	Medcaptain Software	2017SR578507	October 20, 2017
36.	McCurtain HP-60 Infusion Pump UI Software V1.3.0 (麥科田HP-60輸液泵UI軟件V1.3.0)	PRC	Medcaptain Software	2017SR577671	October 20, 2017
37.	McCurtain HP-60 Infusion Pump Driver Software V1.3.0 (麥科田HP-60輸液泵驅動軟件V1.3.0)	PRC	Medcaptain Software	2017SR577743	October 20, 2017
38.	Makita HP-80 Multi-Channel Infusion Workstation Software V1.3.0 (麥科田HP-80多通道輸注工作站軟件V1.3.0)	PRC	Medcaptain Software	2017SR578000	October 20, 2017
39.	McCurtain HP TCI Syringe Pump Safety Monitoring Software V1.3.0 (麥科田HP TCI注射泵安全監控軟件V1.3.0)	PRC	Medcaptain Software	2017SR579542	October 20, 2017
40.	McCurtain HP TCI Syringe Pump UI Software V1.3.0 (麥科田HP TCI注射泵UI軟件V1.3.0)	PRC	Medcaptain Software	2017SR579536	October 20, 2017
41.	McCurtain HP TCI Syringe Pump Driver Software V1.3.0 (麥科田HP TCI注射泵驅動軟件V1.3.0)	PRC	Medcaptain Software	2017SR581206	October 23, 2017
42.	Makita HP-30 Syringe Pump Safety Monitoring Software V1.3.0 (麥科田HP-30注射泵安全監控軟件V1.3.0)	PRC	Medcaptain Software	2017SR591947	October 27, 2017
43.	Vimax Information Collection Software V1.0 (唯醫薈信息採集軟件V1.0)	PRC	Vedkang Medical	2023SR0921623	August 11, 2023

APPENDIX IV STATUTORY AND GENERAL INFORMATION

(iv) Domain Name

As of the Latest Practicable Date, the following domain names have been registered in the name of the relevant member of our Group which are considered by us to be or may be material to our business:

No.	Domain name	Registered Owner	Date of Registration
1.	medcaptain.com	Our Company	February 1, 2021
2.	medciot.com	Our Company	January 26, 2021
3.	medcaptain.com.cn	Our Company	March 8, 2021
4.	mabsky.com	Mabsky	October 29, 2020
5.	runpubio.cn	Runpu Biotech	March 9, 2020
6.	vedkang.com	Vedkang Medical	August 24, 2023
7.	endotop.com	Changzhou Jiuhong	January 5, 2024
8.	jiuhongmed.com	Changzhou Jiuhong	February 18, 2024

3. FURTHER INFORMATION ABOUT OUR DIRECTORS

A. Particulars of Directors’ Contracts

Each of our executive Directors and Ms. Li has entered into a service contract with our Company on June 28, 2024, with a term of three years commencing on the same day. Each of our independent non-executive Directors has entered into a letter of appointment with our Company on June 28, 2024. The service contracts and letters of appointment may be renewed in accordance with our Articles of Association and the applicable laws, rules and regulations. Save as disclosed above, none of our Directors has or is proposed to have a service contract with any of our Group (other than contracts expiring or determinable by the relevant employer within one year without the payment of compensation (other than statutory compensation)).

4. DISCLOSURE OF INTERESTS

A. Directors or Chief Executives

Save as disclosed below, immediately following the unwinding of the WVR structure, the Conversion of the Unlisted Shares into H Shares and upon completion of the [REDACTED] (and assuming the [REDACTED] is not exercised and taking into account the share options granted under the [REDACTED] Share Option Scheme), none of our Directors or the chief executive of our Company has any interest and/or short position in our Shares, underlying Shares and debentures of our Company or any of its associated corporations (within the meaning of Part XV of the SFO), which will have to be notified to us and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which has been taken or is deemed to have under such provisions of the SFO) or which will be required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or will be required, pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers in Appendix C3 to the Listing Rules to be notified to our Company and the Stock Exchange.

Name of Director	Capacity/ Nature of interest	Number and description of Shares held ⁽¹⁾	Approximate percentage of shareholding of H Shares/ Unlisted Shares in our Company	Approximate percentage of shareholding in the total share capital of our Company ⁽²⁾
Mr. Liu.	Beneficial owner ⁽³⁾ Interest of spouse and held jointly with another person ⁽³⁾	[REDACTED] [REDACTED]	[REDACTED] [REDACTED]	[REDACTED] [REDACTED]

APPENDIX IV STATUTORY AND GENERAL INFORMATION

Name of Director	Capacity/ Nature of interest	Number and description of Shares held ⁽¹⁾	Approximate percentage of shareholding of H Shares/ Unlisted Shares in our Company	Approximate percentage of shareholding in the total share capital of our Company ⁽²⁾
Ms. Li	Beneficial owner	[REDACTED]	[REDACTED]	[REDACTED]
	Interest of controlled corporations ⁽³⁾	[REDACTED]	[REDACTED]	[REDACTED]
	Interests of spouse and held jointly with another person ⁽³⁾	[REDACTED]	[REDACTED]	[REDACTED]
Mr. Zhong	Beneficial owner ⁽³⁾	[REDACTED]	[REDACTED]	[REDACTED]
	Interest of controlled corporations ⁽³⁾	[REDACTED]	[REDACTED]	[REDACTED]
	Interests held jointly with another person ⁽³⁾	[REDACTED]	[REDACTED]	[REDACTED]
Mr. YAN Renzong (顏仁仲)	Beneficial owner ⁽⁴⁾	[REDACTED]	[REDACTED]	[REDACTED]

Notes:

- (1) All interests stated above are long positions.
- (2) Calculated based on the total number of [REDACTED] Shares in issue immediately following the unwinding of WVR structure, the Conversion of Unlisted Shares into H Shares and upon completion of the [REDACTED] and assuming the [REDACTED] has not been exercised, without taking into account any H Shares that may be issued pursuant to the exercise of Options which have been granted under the [REDACTED] Share Option Scheme.
- (3) Mr. Liu and Ms. Li are spouses. Mr. Liu, Mr. Zhong and Ms. Li are parties acting in concert pursuant to the Concert Party Agreement dated November 18, 2020. See “History, Development and Corporate Structure — Concert Party Arrangement” for further information of such arrangement. In addition, the Concert Parties are also deemed to control and be interested in Shares held by certain of our Employees Incentive Platforms: (i) Ms. Li is the general partner of Juxian Kangzhong LP, Ruisen Kangzhong LP, Jucai Kangzhong LP, Ruiyu Kangzhong LP, Ruqian Kangzhong LP and Ruikun Kangzhong LP; and (ii) Mr. Zhong is the general partner of Ruixin Kangzhong LP. Accordingly, the Concert Parties are deemed to be interested in and have control over Shares held by the aforesaid Employees Incentive Platforms pursuant to the Listing Rules and the SFO.

Further, Mr. Liu and Mr. Zhong were granted share options under the [REDACTED] Share Option Scheme to subscribe for up to [REDACTED] and [REDACTED] H Shares, respectively, subject to the conditions (including exercise conditions) of those options. For details, please refer to the subsection headed “— 5. [REDACTED] Share Option Scheme” in this appendix. As such, the Concert Parties are also deemed to be interested in the underlying H Shares of such share options.
- (4) Mr. Yan was granted share options under the [REDACTED] Share Option Scheme to subscribe for [REDACTED] H Shares, subject to the conditions (including exercise conditions) of those options. For details, please refer to the subsection headed “— 5. [REDACTED] Share Option Scheme” in this appendix.

B. Substantial shareholders of our Company

Save as disclosed in the section headed “Substantial Shareholders” in this document, as of the Latest Practicable Date, our Directors are not aware of any other person who will, immediately following the unwinding of the WVR structure, the Conversion of Unlisted Shares into H Shares and upon completion of the [REDACTED] have an interest or short position in our Shares or the underlying Shares which are required to be disclosed to our Company and the Stock Exchange under the provisions of Division 2 and 3 of Part XV of the SFO.

APPENDIX IV STATUTORY AND GENERAL INFORMATION

C. Substantial shareholders of other members of our Group

So far as our Directors are aware, as at the Latest Practicable Date, the following person (other than our Directors or chief executive of our Company) was, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of other members of our Group.

Name of members of our Group	Name of Shareholder	Approximate percentage shareholding
Jiangsu Tuyun	ZHUANG Xiaojin ⁽¹⁾	20.00%

Note:

- (1) As at the Latest Practicable Date, Jiangsu Tuyun was owned as to 80% by Vedkang Medical and 20% by Changzhou Xinchuang Zhicheng Venture Capital Partnership (Limited Partnership) (常州信創智誠創業投資合夥企業(有限合夥)) (“**Xinchuang Zhicheng LP**”), a limited partnership established in the PRC. Mr. ZHUANG is the general partner of Xinchuang Zhicheng LP and the largest limited partner holding more than 90% of the limited partnership interest in Xinchuang Zhicheng LP.

D. Disclaimers

Save as disclosed in this document:

- (i) none of our Directors is a director or employee of a company which is expected to have an interest in our Shares falling to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO once our Shares have been [REDACTED];
- (ii) none of our Directors nor any of the parties listed in “— 6. Other Information — G. Qualification of Experts” in this Appendix is materially interested in any contract or arrangement subsisting at the date of this document which is significant in relation to our business;
- (iii) none of our Directors nor any of the parties listed in “— 6. Other Information — G. Qualification of Experts” in this Appendix is interested in our promotion, or in any assets which have, within two years immediately preceding the issue of this document, been acquired or disposed of by or leased to us, or are proposed to be acquired or disposed of by or leased to our Company;
- (iv) none of the parties listed in the paragraph headed “— 6. Other Information — G. Qualification of Experts” in this Appendix: (a) is interested legally or beneficially in any of our Shares or any shares in any of our subsidiaries; or (b) has any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for our securities; and
- (v) none of our Directors or their respective associates or any Shareholders of our Company (who to the knowledge of our Directors owns more than 5% of our issued share capital) has any interest in our five largest suppliers or our five largest customers.

5. [REDACTED] SHARE OPTION SCHEME

The Company has adopted a [REDACTED] share option scheme by a resolution of our Shareholders on December 16, 2024 to attract and retain the talents and to provide incentives that align the interests of shareholders, our Company and personnel having a direct impact on our business and operations, for long-term development of the Company (the “[REDACTED] Share

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

Option Scheme”). Given no further options will be granted under the [REDACTED] Share Option Scheme upon the [REDACTED], the terms of the [REDACTED] Share Option Scheme are not subject to the provisions of Chapter 17 of the Listing Rules.

The following is a summary of the principal terms of the [REDACTED] Share Option Scheme:

(i) Objectives

The main purposes of the [REDACTED] Share Option Scheme are to (a) further enhance the Company’s long-term incentivization mechanism for the directors, senior management, core business personnel, core technical personnel or any other personnel of the Group as the Board deems appropriate with further opportunities, so as to attract, motivate and retain outstanding and experienced personnel who are directly relevant to the continuous operation, development and long-term growth of the Group, and to encourage their proactiveness, responsibility and commitment towards the Group; (b) align the Group’s interests with those of the Shareholders and key personnel in respect of the Group’s long-term development; and (c) better promote the strategic development and business goals of the Group.

(ii) Administration

The [REDACTED] Share Option Scheme is subject to the administration of the Board. The decision of the Board is final and binding. Without prejudice to the Board’s general power of management, it may delegate such power to any director(s) and/or any relevant committee of the Board (such persons, together with our Board and any person authorized by our Board, “**Relevant Authorized Persons**”).

(iii) Eligibility

The following persons are eligible to participate in the [REDACTED] Share Option Scheme (the “**Eligible Participants**”):

- (a) our Directors (excluding the independent non-executive Directors);
- (b) directors, senior management, core business personnel, core technical personnel of our Group;
- (c) other personnel who have a direct impact or contribution to our Group’s business, financial performance and future development (including foreign employees who are directly relevant to the sustainability, stability and long-term development of our overseas business); and
- (d) any other personnel of our Group as the Relevant Authorized Persons deem appropriate (excluding the independent non-executive Directors).

The Relevant Authorized Persons shall, at their sole discretion, select any Eligible Participants to be grantees (the “**Selected Participants**”) of options under the [REDACTED] Share Option Scheme (the “**Option(s)**”) in accordance with the PRC Company Law, the Securities Law, the Articles or any other applicable laws or regulations, except where a person is prohibited by the applicable laws to hold any shares in a company or participate in any share incentive schemes of a company.

(iv) Maximum Number of H Shares Involved

The Shares subject to the Options to be granted under the [REDACTED] Share Option Scheme shall be H Shares. Each Option granted represent the right to purchase one H Share within the Exercise Period (as defined below) at the Exercise Price (as defined below). The number of H Shares underlying the Options shall be subject to corresponding adjustments in the event of a

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

capitalization issue, bonus issue, stock split, rights issue and/or share consolidation of the Company in order to prevent the dilution or enlargement of the benefits or potential benefits intended to be made available under the [REDACTED] Share Option Scheme.

The maximum number of H Shares to be granted under the [REDACTED] Share Option Scheme shall not exceed [REDACTED] H Shares, representing approximately [REDACTED]% of the total issued share capital of our Company at the time when the scheme is approved by our Shareholders at a general meeting and approximately [REDACTED] of the total issued share capital of our Company immediately following the Conversion of Unlisted Shares into H Shares and upon completion of the [REDACTED] (assuming the [REDACTED] has not been exercised and the Options granted have not been exercised and remain outstanding).

(v) Grantees

As of the date of this document, there are a total of 360 grantees under the [REDACTED] Share Option Scheme, which include 3 Directors, 4 members of our senior management (other than the Directors), 3 connected persons who are not the Directors and 350 other employees.

(vi) Duration

The [REDACTED] Share Option Scheme shall be valid and effective for the period of time commencing from the date of approval by our Shareholders (the “Effective Date”) and expiring on the day when all Options granted under the [REDACTED] Share Option Scheme are exercised or cancelled. With respect to all such Options that remain outstanding upon expiration of the [REDACTED] Option Scheme, the provisions of the [REDACTED] Share Option Scheme shall in all relevant respects remain in full force and effect and all such outstanding Option may continue to be exercisable in accordance with their terms of grant. For the avoidance of doubt, no Options will be granted from the [REDACTED] onwards.

(vii) Grant of Options

Subject to the terms of the [REDACTED] Share Option Scheme, the Relevant Authorized Persons shall be entitled at any time before the [REDACTED] to make an offer in writing to grant Options to any Selected Participant(s) as they may in their sole discretion select. For the avoidance of doubt, no Options will be granted from the [REDACTED] onwards.

An offer of the grant of an Option shall be made to any Selected Participants in such form as the Relevant Authorized Persons may from time to time determine specifying, amongst others and as the case may be, the number of Options and number of H Shares to be issued upon exercising the Options, the effective date of the grant, the vesting conditions (including any performance targets) and vesting period, the subscription price (if any), the Exercise Price and the Exercise Period.

Once the offer of the grant of an Option is accepted in writing by a Selected Participant, such Option shall be deemed as being granted immediately before [REDACTED] and shall take effect upon [REDACTED]. Any grant of Options may be accepted in whole or in part. If a Selected Participant (i) does not accept the offer or (ii) is not deemed to accept the offer in the manner specified in the grant letter, or (iii) is no longer an Eligible Participant and/or eligible to be a Selected Participant after the grant letter has been issued, he/she will be deemed to have irrevocably rejected the offer and the offer will lapse automatically without further notice.

(viii) Vesting and Exercise of Options

The Relevant Authorized Persons shall have the full discretion to determine any vesting conditions or restrictions (including but not limited to vesting periods or clawback mechanisms, and/or performance targets that a Selected Participant) for the Options of a selected participant. The

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

Relevant Authorized Persons have full discretion to determine these vesting conditions and to make any adjustments or modifications after determining the vesting conditions. Performance targets may include (but are not limited to) the evaluation results of the Selected Participant’s performance indicators, the achievement of planned milestones by the Group or relevant subsidiaries of the Company, and market capitalization milestones. The Relevant Authorized Persons may set different performance targets based on the individual circumstances of each Selected Participant. The Board’s decision on whether the vesting conditions are met are binding and final.

The Options shall not be exercisable before the [REDACTED]. Subject to satisfaction of the relevant conditions of vesting and exercise, the Options shall vest and become exercisable after the [REDACTED] in five batches in accordance with the following arrangement:

Relevant batch of Options	Duration of exercise period of the Options (the “Exercise Period”)	Proportion of exercisable Options to the total number of Options granted to the relevant Selected Participant
First batch of Options	For a period of 12 months commencing first trading day after the expiration of the 12-month period from the [REDACTED] (the “First Exercise Date”)	20%
Second batch of Options	For a period of 12 months commencing first trading day after the expiration of the 12-month period from the First Exercise Date and ending on the last trading day of the 24-month period from the First Exercise Date	20%
Third batch of Options	For a period of 12 months commencing first trading day after the expiration of the 24-month period from the First Exercise Date and ending on the last trading day of the 36-month period from the First Exercise Date	20%
Fourth batch of Options	For a period of 12 months commencing first trading day after the expiration of the 36-month period from the First Exercise Date and ending on the last trading day of the 48-month period from the First Exercise Date	20%
Fifth batch of Options	For a period of 12 months commencing first trading day after the expiration of the 48-month period from the First Exercise Date and ending on the last trading day of the 60-month period from the First Exercise Date	20%

The Exercise Period for the Options granted to an Eligible Participant can commence at a date earlier than that stipulated in the aforementioned table upon approval by the Relevant Authorized Persons and in any of the following circumstances:

- (a) grants to an Eligible Participant whose employment is terminated due to death or disability or occurrence of any out of control event; and

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

- (b) where the Board and/or the Relevant Authorized Persons deem such shorter vesting period to be appropriate and in line with the purpose of the [REDACTED] Share Option Scheme.

If the Relevant Authorized Persons determine that the relevant vesting conditions application to any Selected Participant in respect of the relevant exercise period are not fulfilled in full or in part, the relevant batch of the Options shall neither be exercised nor become exercisable in the next exercise period, and shall be cancelled by our Company. Similarly, if a Selected Participant fails to exercise the Options within the relevant exercise period, the corresponding Options that have not been exercised shall also be cancelled by the Company.

Subject to applicable laws and the terms of the grant letter, Selected Participants have the right to exercise the vested Options within the Exercise Period in such manner as determined by the Relevant Authorized Persons from time to time. On the date of exercise (i.e., any such day on which the H Shares are trading on the Stock Exchange within the Exercise Period specified by the Board or the Relevant Authorized Persons from time to time), Selected Participants shall issue an irrevocable exercise notice to the Company in writing, which shall be in the template determined by the Relevant Authorized Persons from time to time. For the avoidance of doubt, if the exercise notice is delivered or deemed to be delivered on a day when the trading of H Shares is suspended or halted, or when H Shares register of members of the Company is closed, the exercise date will be postponed to the next trading day immediately following the resumption of trading or the reopening of the H Shares register of members of the Company.

(ix) Exercise Price

The exercise price (the “**Exercise Price**”) of the Options granted under the [REDACTED] Share Option Scheme is RMB4.00 per H Share (or such equivalent amount in foreign currency as approved by the Relevant Authorized Persons). The Exercise Price shall be subject to corresponding adjustments in the event of a capitalization issue, bonus issue, distribution of cash dividends, stock split, rights issue and/or share consolidation of the Company in order to prevent the dilution or enlargement of the benefits or potential benefits intended to be made available under the [REDACTED] Share Option Scheme.

(x) Rights attached to the Options

No Selected Participant shall enjoy any rights of a Shareholder, including without limitation, the right to vote at general meetings of the Company and the rights to receive any dividends or distributions, by virtue of the grant of an Option, unless and until such Shares underlying the Option are issued and allotted in accordance with the terms of the [REDACTED] Share Option Scheme.

(xi) Ranking of the Shares

The H Shares to be allotted and issued upon the exercise of an Option shall be subject to the provisions of the Articles and the applicable laws and regulations in force as at the allotment date and shall rank *pari passu* in all respects with the existing fully paid H Shares in issue on the allotment date and accordingly shall entitle the holder to participate in all dividends or other distributions paid or made on or after the allotment date other than any dividend or other distribution previously declared or recommended or resolved to be paid or made if the record date therefor is before the allotment date. Prior to allotment of the H Shares pursuant to the exercise of Options, the Options themselves shall not confer any of the aforesaid rights attached to H Shares to the Selected Participants.

(xii) Lock-up Periods and Restrictions of Transfer

The Selected Participants holding H Shares issued pursuant to exercise of shall comply with the lock-up obligations under the relevant laws and regulations.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

An Option shall be personal to the Selected Participant and shall not be transferrable or assignable. No Selected Participant shall in any way sell, transfer, assign, charge, pledge, mortgage, encumber or create any interest in favor of any third party over the Options in any manner whatsoever or enter into an agreement to do so. Any breach of the foregoing by the Selected Participant shall entitle our Company to cancel any outstanding entitlement of such Selected Participant.

(xiii) Lapse and cancellation of Options

Any outstanding Options of a Selected Participant shall automatically lapse upon the earlier of:

- (a) the expiration of the Exercise Period;
- (b) the commencement of the Company’s liquidation;
- (c) the occurrence of any of the following circumstances with respect to such Selected Participant: (1) violation of the transfer restrictions in respect of the Options; (2) termination of employment for specific reasons; (3) breach of non-compete obligations; (4) negligence in his/her employment; or (5) serious misconduct;
- (d) the date on which such Selected Participant violates any terms or conditions attached to the granted Options; or
- (e) the date on which such Selected Participants fails, is unable, or is no longer eligible to participate in the [REDACTED] Share Option Scheme (including by reasons of retirement or resignation), unless otherwise approved by the Relevant Authorized Persons.

Upon consent by a Selected Participant, the Company can cancel any granted and unvested, or outstanding, Options of such Selected Participant.

(xiv) Alteration of the [REDACTED] Share Option Scheme

Save and except for any material alteration of the terms and conditions of the [REDACTED] Share Option Scheme (including any accelerated vesting or exercise of the Options or decrease of the Exercise Price otherwise than as provided under the [REDACTED] Share Option Scheme) and any alterations to the right of the Relevant Authorized Persons in the alteration of the [REDACTED] Share Option Scheme, the [REDACTED] Share Option Scheme may be altered in any respect by a resolution of the Board.

(xv) Termination of the [REDACTED] Share Option Scheme

The Company may terminate the [REDACTED] Share Option Scheme at any time by a resolution at a general meeting of Shareholders. In such a case, the Company shall no longer grant Options under the [REDACTED] Share Option Scheme. However, the provisions of the [REDACTED] Share Option Scheme shall remain in full force and effect to ensure that any Options granted before the termination of the [REDACTED] Share Option Scheme or under other circumstances specified in the terms and conditions of the [REDACTED] Share Option Scheme can still be validly exercised.

(xvi) Outstanding Options granted under the [REDACTED] Share Option Scheme

As at the date of this document, our Company [has granted] Options to subscribe for a total of [REDACTED] H Shares, representing approximately [REDACTED] of the total issued share capital of our Company immediately following the Conversion of Unlisted Shares into H Shares and

APPENDIX IV STATUTORY AND GENERAL INFORMATION

upon completion of the [REDACTED] (assuming the [REDACTED] has not been exercised and the Options granted have not been exercised and remain outstanding) under the [REDACTED] Share Option Scheme. Assuming full vesting and exercise of the outstanding Options and the [REDACTED] has not been exercised, the shareholding percentage of our Shareholders immediately following the [REDACTED] would be diluted by approximately [REDACTED] as calculated based on [REDACTED] Shares then in issue. For the avoidance of doubt, our Company will not grant further Options under the [REDACTED] Incentive Scheme after the [REDACTED].

The table below sets out the details of Options granted to our Directors, members of the senior management and connected persons who are not our Directors or members of the senior management, under the [REDACTED] Share Option Scheme:

Name of Grantee	Address	Position(s) held within our Group	Total Number of H Shares Underlying the Options Granted	Vesting Period	Exercise Price per H Share (RMB)	Approximate Percentage of Shareholding in the Total Issued Share Capital of our Company ^(Note)
Directors						
Mr. Liu	Room 1801, Block C, Building 1 Shenwanhui Yun Center Phase One Baishi 3rd Road Nanshan District, Shenzhen PRC	Executive Director, chairman of the Board and general manager	[REDACTED]	5 years from the First Exercise Date	4.00	[REDACTED]%
Mr. Zhong	Room 3401, Block B China Resources City Runfu Phase II 28 Tonggu Road Yuehai Street Nanshan District, Shenzhen PRC	Executive Director, vice chairman of our Board and deputy general manager	[REDACTED]	5 years from the First Exercise Date	4.00	[REDACTED]%
Mr. YAN Renzhong (顏仁仲)	Room 212, Block 2 Nantian Building No. 2 Baihua 3rd Road Futian District, Shenzhen PRC	Executive Director and board secretary	[REDACTED]	5 years from the First Exercise Date	4.00	[REDACTED]%
Members of the senior management						
Mr. LUO Jun (羅軍)	Room 11D, Building 3 Phase 6, Xinghai Mingcheng Qianhai Road Nanshan District, Shenzhen PRC	Deputy general manager	[REDACTED]	5 years from the First Exercise Date	4.00	[REDACTED]%

APPENDIX IV STATUTORY AND GENERAL INFORMATION

Name of Grantee	Address	Position(s) held within our Group	Total Number of H Shares Underlying the Options Granted	Vesting Period	Exercise Price per H Share (RMB)	Approximate Percentage of Shareholding in the Total Issued Share Capital of our Company ^(Note)
Mr. LIU Qisong (劉奇松) . . .	Room 108, Building 1 Jingmei Huayuan 37 Hubin Road Bao'an District, Shenzhen PRC	Deputy general manager	[REDACTED]	5 years from the First Exercise Date	4.00	[REDACTED]%
Mr. YUAN Jia (袁加)	Room 17B, Building 30 Chunhua Sijiyuan Longhua District, Shenzhen PRC	Chief financial officer	[REDACTED]	5 years from the First Exercise Date	4.00	[REDACTED]%
Mr. WANG Bin (王斌)	2-2305, Tianjian Yueguifu Nanshan Residential Area Nanshan District, Shenzhen PRC	Deputy general manager	[REDACTED]	5 years from the First Exercise Date	4.00	[REDACTED]%
Connected persons (other than the Directors)						
Mr. GAO Xiaoming (高小明) . . .	37 Kysbie Close, Abingdon, OX14 1XY, United Kingdom	CEO of Penlon	[REDACTED]	5 years from the First Exercise Date	4.00	[REDACTED]%
Ms. Linda Jane MOSS	3 Childrey Way, East Challow, Wantage, Oxfordshire, OX12 9RX, United Kingdom	Human resources director	[REDACTED]	5 years from the First Exercise Date	4.00	[REDACTED]%
Ms. XIAO Tianshi (肖天石) . . .	29 Quakers Court, Abingdon, OX14 3PY, United Kingdom	Head of Finance of Penlon	[REDACTED]	5 years from the First Exercise Date	4.00	[REDACTED]%

Note: Calculated based on the total number of [REDACTED] Shares in issue immediately following the Conversion of Unlisted Shares into H Shares and upon completion of the [REDACTED] and assuming the [REDACTED] has not been exercised, without taking into account any H Shares that may be issued pursuant to the exercise of Options which have been granted under the [REDACTED] Share Option Scheme.

As of the date of this document, other than 3 Directors, 4 senior management of the Company (who are not Directors) and 3 connected persons of the Company who are director(s) or supervisor(s) of the Company's subsidiaries, as disclosed above, no options were granted to any Directors, senior management or other connected persons of the Company under the [REDACTED] Share Option Scheme. As of the date of this document, other than (i) 3 Directors, (ii) 4 senior management members of the Company, and (iii) 3 connected persons of the Company who are director(s) or supervisor(s) of the Company's subsidiaries as set out above, the other 350 grantees have been granted in aggregate [REDACTED] share options which were outstanding under the [REDACTED] Share Option Scheme, for which up to [REDACTED] H Shares may be issued, representing approximately [REDACTED] of the total issued share capital of our Company upon completion of the [REDACTED] (assuming the [REDACTED] is not exercised and no Shares are issued pursuant to the share options granted under the [REDACTED] Share Option Scheme), with

APPENDIX IV STATUTORY AND GENERAL INFORMATION

the number of H Shares to be issued upon exercise of the relevant options ranging from 5,000 H Shares to 550,000 H Shares (assuming the actual exercisable options of the Selected Participants equals to the options respectively granted to them).

The table below shows the details of the options granted to such other grantees under the [REDACTED] Share Option Scheme which were outstanding as of the date of this document:

Range of number of H Shares under the outstanding options	Number of grantees	Aggregate Number of H Shares Underlying the Options Granted	Vesting Period	Exercise Price per H Share	Approximate Percentage of Shareholding in the Total Issued Share Capital of our Company ^(Note)
				(RMB)	
250,000 to 550,000 .	12	[REDACTED]	5 years from the First Exercise Date	4.00	[REDACTED]%
100,000 to 225,000 .	19	[REDACTED]	5 years from the First Exercise Date	4.00	[REDACTED]%
50,000 to 90,000 . . .	66	[REDACTED]	5 years from the First Exercise Date	4.00	[REDACTED]%
5,000 to 42,500	253	[REDACTED]	5 years from the First Exercise Date	4.00	[REDACTED]%

Note: Calculated based on the total number of [REDACTED] Shares in issue immediately following the Conversion of Unlisted Shares into H Shares and upon completion of the [REDACTED] and assuming the [REDACTED] has not been exercised, without taking into account any H Shares that may be issued pursuant to the exercise of Options which have been granted under the [REDACTED] Share Option Scheme.

(xvii) General

An application has been made to the Listing Committee of the Stock Exchange for the [REDACTED] of and the permission to [REDACTED] the H Shares which may be issued pursuant to the exercise of any Options which may be granted under the [REDACTED] Share Option Scheme.

6. OTHER INFORMATION

A. Estate Duty

We have been advised that no material liability for estate duty under the PRC law is likely to fall upon our Company or any member of our Group.

B. Litigation

As of the Latest Practicable Date, we were not involved in any material litigation, arbitration or administrative proceedings, and so far as our Directors are aware, no such material litigation, arbitration or administrative proceedings are pending or threatened against any member of our Group.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

C. Joint Sponsors

Each of the Joint Sponsors has declared its independence pursuant to Rule 3A.07 of the Listing Rules.

The Joint Sponsors have made an application on our behalf to the Stock Exchange for the [REDACTED] of, and permission to [REDACTED], the H Shares in issue and the H Shares to be issued pursuant to the [REDACTED] (including any H Shares which may fall to be issued pursuant to the exercise of the [REDACTED] and the exercise of the Options pursuant to the [REDACTED] Share Option Scheme). All necessary arrangements have been made to enable the H Shares to be admitted into [REDACTED].

We have entered into an engagement agreement with the Joint Sponsors, pursuant to which we agreed to pay a total amount of US\$1 million to the Joint Sponsors to act as our sponsors to our Company in the [REDACTED].

D. Compliance Adviser

We have appointed UOB Kay Hian (Hong Kong) Limited as our compliance adviser in compliance with Rule 3A.19 of the Listing Rules.

E. Preliminary Expenses

As of the Latest Practicable Date, our Company has not incurred material preliminary expenses.

F. Promoters

The promoters of our Company are Mr. Liu, Mr. Zhong, Ms. Li, Mr. LI Dongcen, Juxian Kangzhong LP, Jucai Kangzhong LP, Ruisen Kangzhong LP, Ruikun Kangzhong LP, Ruiqian Kangzhong LP, Ruiyu Kangzhong LP, the Series A Investors, the Series B Investor, the Series C Investors, Linkway Cornerstone and Cowin Asset Management.

Save as disclosed in this document, within the two years immediately preceding the date of this document, no cash, securities or other interest have been paid, allotted or given to the above promoters in connection with the [REDACTED] or related transactions in this document.

G. Qualification of Experts

The qualifications of the experts, as defined under the [REDACTED] Rules, who have given their opinions or advice in this document, are as follows:

Name	Qualification
Morgan Stanley Asia Limited . . .	A licensed corporation under the SFO to carry on Type 1 (dealing in securities), Type 4 (advising on securities), Type 5 (advising on futures contracts), Type 6 (advising on corporate finance) and Type 9 (asset management) regulated activities as defined under the SFO
Huatai Financial Holdings (Hong Kong) Limited.	A corporation licensed to conduct Type 1 (dealing in securities), Type 2 (dealing in futures contracts), Type 3 (leveraged foreign exchange trading), Type 4 (advising on securities), Type 6 (advising on corporate finance), Type 7 (providing automated trading services) and Type 9 (asset management) of the regulated activities as defined under the SFO

APPENDIX IV STATUTORY AND GENERAL INFORMATION

Name	Qualification
Ernst & Young	Certified Public Accountants under Professional Accountants Ordinance (Cap. 50 of the Laws of Hong Kong) Registered Public Interest Entity Auditor under Financial Reporting Council Ordinance (Cap. 588 of the Laws of Hong Kong)
Jia Yuan Law Offices	Legal advisor as to PRC laws
Hogan Lovells	Legal advisor as to international sanctions law
China Insights Industry Consultancy Limited	Industry consultant

H. Consents of Experts

Each of the experts as referred to in “— 6. Other Information — G. Qualification of Experts” in this Appendix has given, and has not withdrawn, its respective written consents to the issue of this document with the inclusion of its reports and/or letter and/or opinion and/or the references to its name included herein in the form and context in which it is respectively included. As of the Latest Practicable Date, none of the experts named above has any shareholding interests in any member of our Group or the right (other than the penal provisions) of sections 44A of the Companies (Winding Up and Miscellaneous Provisions) Ordinance so far as applicable.

I. Taxation of Holders of H Shares

The sale, purchase and transfer of H Shares are subject to Hong Kong stamp duty if such sale, purchase and transfer are effected on the H Share register of members of our Company, including in circumstances where such transaction is effected on the Stock Exchange. The current rate charged on each of the seller and purchaser is 0.1% of the consideration or, if higher, the fair value of the H Shares being sold or transferred.

J. No Material Adverse Change

Save as disclosed in this document, our Directors confirm that there has been no material adverse change in our financial or operational position since December 31, 2025 and up to the Latest Practicable Date.

K. Binding effect

This document shall have the effect, if an application is made in pursuance hereof, of rendering all persons concerned bound by all the provisions (other than the penal provisions) of sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance so far as applicable.

L. Related Party Transactions

Within the two years immediately preceding the date of this document, we have entered into the related party transactions as described in Note 41 to the financial information in the Accountants’ Report set out in Appendix I to this document.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

M. Agency Fees or Commissions Paid or Payable

Save as disclosed in this document, no commissions, discounts, brokerages or other special terms have been granted in connection with the issue or sale of any capital of any member of our Group within the two years preceding the date of this document.

N. Miscellaneous

Save as disclosed in this document:

- (i) within the two years immediately preceding the date of this document, we have not issued or agreed to issue any share or loan capital fully or partly paid either for cash or for a consideration other than cash;
- (ii) no share or loan capital of our Group, if any, is under option or is agreed conditionally or unconditionally to be put under option;
- (iii) we have not issued or agreed to issue any founder shares, management shares or deferred shares;
- (iv) our Company has no outstanding convertible debt securities or debentures;
- (v) there are no restrictions affecting the remittance of profits or repatriation of capital by us into Hong Kong from outside Hong Kong;
- (vi) within the two years immediately preceding the date of this document, no commission, discount, brokerage or other special term has been granted in connection with the issue or sale of any capital of our Company;
- (vii) there is no arrangement under which future dividends are waived or agreed to be waived;
- (viii) there has been no interruption in our business which may have or have had a significant effect on the financial position in the last 12 months; and
- (ix) none of the equity and debt securities of our Company, if any, is listed or dealt with in any other stock exchange nor is any listing or permission to deal being or proposed to be sought.

O. Bilingual Document

The English language and Chinese language versions of this document are being published separately, in reliance upon the exemption provided by section 4 of the Companies (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).